Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464982 | 0.87 | GAA (0.51) | MEN1KMT2ACXCR2ALDH1A1TDP1 | |
| SCHEMBL31555014 | 0.81 | MAPT (0.54) | MEN1KMT2ACXCR2ALDH1A1TDP1 | |
| SCHEMBL15257085 | 0.78 | MAPT (0.53) | MEN1KMT2AALDH1A1TDP1HTT | |
| SCHEMBL3374367 | 0.77 | TDP1 (0.47) | MEN1KMT2ACXCR2ALDH1A1TDP1 | |
| SCHEMBL9541733 | 0.77 | MEN1 (0.46) | MEN1KMT2AALDH1A1TDP1CYP3A4 | |
| Hydrochloric Acid SCHEMBL9594716 | 0.76 | TDP1 (0.46) | MEN1KMT2ACXCR2ALDH1A1TDP1 | |
| SCHEMBL30864252 | 0.75 | CYP19A1 (0.56) | MEN1KMT2AALDH1A1CYP3A4HPGD | |
| SCHEMBL1290807 | 0.75 | CYP19A1 (0.56) | MEN1KMT2AALDH1A1CYP3A4HPGD | |
| SCHEMBL396053 | 0.75 | SMN1; SMN2 (0.57) | MEN1KMT2ACXCR2TDP1CXCR1 | |
| SCHEMBL1008274 | 0.75 | HTT (0.49) | MEN1KMT2ACXCR2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2016138352-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2015143376-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MEN1 2491/4885KMT2A 206/4885CXCR2 2272/4885 |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MEN1 2491/4885KMT2A 206/4885CXCR2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.